Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation
Atrial Fibrillation (AF) is associated with significant increase of stroke and other ischemic events risk. Anticoagulation to prevent ischemic strokes is a critical component of this condition management. Direct oral anticoagulants (DOACs)—with more predictable pharmacokinetics, ease of use and favo...
Saved in:
| Main Author: | article Editorial |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
InterMedservice
2022-03-01
|
| Series: | Евразийский Кардиологический Журнал |
| Online Access: | https://www.heartj.asia/jour/article/view/6308 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Association of rivaroxaban and apixaban therapy with major ischemic or bleeding events in patients with atrial fibrillation. Retrospective cohort real-world evidence study. Press release
by: article Editorial
Published: (2022-03-01) -
CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: S. V. Nedogoda, et al.
Published: (2017-03-01) -
Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK
by: Kevin Bowrin, et al.
Published: (2020-01-01) -
Safety and effectiveness of Rivaroxaban, Dabigatran and Apixaban in patients with non-valvular atrial fibrillation for stroke prophylaxis
by: Ceyda Tanoğlu, et al.
Published: (2025-07-01) -
PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION
by: A. V. Rudakova
Published: (2015-09-01)